Neximmune IncNASDAQ:NEXINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE3.1500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.0000/ 2
- Ask / Lots3.3800/ 1
- Open / Previous Close3.4200 / 3.1500
- Day Range
- 52 Week Range
- Volume33,705
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NEXI |
|---|---|---|
| 09:36 ET | 167 | 3.42 |
| 09:39 ET | 100 | 3.43 |
| 09:41 ET | 221 | 3.4293 |
| 09:45 ET | 1769 | 3.4201 |
| 09:50 ET | 430 | 3.42 |
| 09:54 ET | 400 | 3.4001 |
| 10:03 ET | 1200 | 3.26 |
| 10:06 ET | 500 | 3.14 |
| 10:08 ET | 600 | 3.2322 |
| 10:12 ET | 1000 | 3.2958 |
| 10:19 ET | 500 | 3.29 |
| 10:21 ET | 800 | 3.29 |
| 10:24 ET | 1200 | 3.2999 |
| 10:30 ET | 100 | 3.26 |
| 10:32 ET | 950 | 3.2965 |
| 10:35 ET | 100 | 3.3 |
| 10:37 ET | 700 | 3.2823 |
| 10:39 ET | 1000 | 3.2823 |
| 10:44 ET | 750 | 3.2823 |
| 10:46 ET | 3865 | 3.35 |
| 10:50 ET | 300 | 3.34 |
| 10:53 ET | 2412 | 3.325 |
| 11:04 ET | 200 | 3.3523 |
| 11:13 ET | 100 | 3.36 |
| 11:26 ET | 200 | 3.3484 |
| 11:38 ET | 1000 | 3.3716 |
| 11:56 ET | 300 | 3.33 |
| 12:03 ET | 200 | 3.36 |
| 01:10 ET | 400 | 3.32 |
| 01:12 ET | 100 | 3.36 |
| 01:17 ET | 300 | 3.3716 |
| 02:02 ET | 100 | 3.335 |
| 02:09 ET | 1300 | 3.34 |
| 02:27 ET | 400 | 3.33 |
| 02:42 ET | 2700 | 3.32 |
| 03:02 ET | 1398 | 3.25 |
| 03:18 ET | 250 | 3.2932 |
| 03:50 ET | 700 | 3.281 |
| 03:54 ET | 100 | 3.29 |
| 03:59 ET | 116 | 3.15 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neximmune Inc | 4.5M | -0.1x | --- |
Mymd Pharmaceuticals Inc | 4.5M | -0.4x | --- |
Zyversa Therapeutics Inc | 4.4M | 0.0x | --- |
Genprex Inc | 4.4M | -0.1x | --- |
Artelo Biosciences Inc | 4.7M | -0.4x | --- |
Tharimmune Inc | 4.3M | 0.0x | --- |
Company Information
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company’s T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. It is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Contact Information
- Headquarters
- 9119 Gaither RoadGAITHERSBURG, MD, United States 20878
- Phone
- 301-825-9810
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Sol Barer
- President, Chief Executive Officer, Director
- Kristi Jones
- Principal Financial and Accounting Officer
- Timothy Stover
- Interim Chief Financial Officer (Principal Financial and Accounting Officer)
- Albert Marchio
- Chief Scientific Officer
- Mathias Oelke
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-42.01 |
Book Value | $30.96 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
